The strategic objectives are to prove the concept of AT2 receptor agonism (the therapeutic platform) as a basis for treatment of human diseases in the cardiovascular area as well as other areas, where there are important unmet medical needs.
To develop candidate drug molecules based on the proven AT2 receptor platform to clinical drug entities for human acute and chronic use through safety stages and clinical stages for major cardiovascular conditions as well as other non-cardiovascular indications.
Last, but not least to enter into collaboration and licensing with pharmaceutical companies for maximized development opportunities of company assets at times when this is deemed optimal and in harmony with company business objectives.